These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25780441)

  • 1. Prognostic value of excision repair cross-complementation group 1 expression in gastric cancer: A meta-analysis.
    Song P; Yin Q; Lu M; Fu BO; Wang B; Zhao Q
    Exp Ther Med; 2015 Apr; 9(4):1393-1400. PubMed ID: 25780441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis.
    Yao A; Wang Y; Peng X; Ye R; Wang Q; Qi Y; Zhou F
    J Cancer Res Clin Oncol; 2014 Dec; 140(12):2107-17. PubMed ID: 24994039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.
    Bišof V; Zajc Petranović M; Rakušić Z; Samardžić KR; Juretić A
    Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2305-17. PubMed ID: 26179868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of excision repair cross-complementation group 1 (ERCC1) in patients with small cell lung cancer (SCLC) receiving platinum-based chemotherapy: evidence from meta-analysis.
    Yang Y; Luo X; Yang N; Feng R; Xian L
    PLoS One; 2014; 9(11):e111651. PubMed ID: 25375151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    Liu YP; Ling Y; Qi QF; Zhang YP; Zhang CS; Zhu CT; Wang MH; Pan YD
    Oncol Lett; 2013 Mar; 5(3):935-942. PubMed ID: 23426424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis.
    Wei KK; Jiang L; Wei YY; Wang YF; Qian XK; Dai Q; Guan QL
    Tumour Biol; 2014 Sep; 35(9):8721-31. PubMed ID: 24870596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERCC1 expression levels predict the outcome of platinum-based chemotherapies in advanced bladder cancer: a meta-analysis.
    Li S; Wu J; Chen Y; Tang W; Peng Q; Deng Y; Xie L; Wang J; Huang S; Li R; Qin X; Zhao J
    Anticancer Drugs; 2014 Jan; 25(1):106-14. PubMed ID: 24025563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern China.
    Deng Q; Yang H; Lin Y; Qiu Y; Gu X; He P; Zhao M; Wang H; Xu Y; Lin Y; Jiang J; He J; Zhou JX
    Int J Clin Exp Pathol; 2014; 7(12):8312-21. PubMed ID: 25674197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of p38MAPK-mediated excision repair cross-complementation 1 expression on prognosis of patients with non-small cell lung cancer.
    He D; Ma X; Wu Z; Wang Y; Zhao S; Han F; Sun W
    Oncol Lett; 2017 Sep; 14(3):3463-3472. PubMed ID: 28927101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The roles of excision repair cross-complementation group1 in objective response after cisplatin-based concurrent chemoradiotherapy and survival in head and neck cancers: a systematic review and meta-analysis.
    Gao Y; Liu D
    Oral Oncol; 2015 Jun; 51(6):570-7. PubMed ID: 25857670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy.
    Ozcan MF; Dizdar O; Dincer N; Balcı S; Guler G; Gok B; Pektas G; Seker MM; Aksoy S; Arslan C; Yalcin S; Balbay MD
    Urol Oncol; 2013 Nov; 31(8):1709-15. PubMed ID: 22863869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy.
    Li MX; Bi XY; Zhao H; Huang Z; Han Y; Zhao DB; Zhao JJ; Cai JQ
    Chin Med J (Engl); 2016 Mar; 129(5):586-93. PubMed ID: 26904994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis.
    Ma SC; Zhao Y; Zhang T; Ling XL; Zhao D
    Onco Targets Ther; 2015; 8():641-8. PubMed ID: 25834456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
    Qi YJ; Cui S; Yang YZ; Han JQ; Cai BJ; Sheng CF; Ma Y; Wuren T; Ge RL
    J Cancer Res Ther; 2013; 9(3):410-5. PubMed ID: 24125975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt.
    Kassem AB; Salem SE; Abdelrahim ME; Said AS; Salahuddin A; Hussein MM; Bahnassy AA
    Exp Mol Pathol; 2017 Feb; 102(1):78-85. PubMed ID: 28088319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of ERCC1 expression in postoperative patients with gastric cancer.
    Wang J; Zhou XQ; Li JY; Cheng JF; Zeng XN; Li X; Liu P
    Chin J Cancer Res; 2014 Jun; 26(3):323-30. PubMed ID: 25035660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
    Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
    J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies.
    Qian YY; Liu XY; Wu Q; Song X; Chen XF; Liu YQ; Pei D; Shen LZ; Shu YQ
    Asian Pac J Cancer Prev; 2014; 15(19):8383-90. PubMed ID: 25339033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum- based chemotherapy in ovarian cancer.
    Li FY; Ren XB; Xie XY; Zhang J
    Asian Pac J Cancer Prev; 2013; 14(12):7203-6. PubMed ID: 24460276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.